StockData
Danaher Corp logo

Danaher Corp

DHRNYSEIndustrial Instruments For Measurement, Display, and ControlFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 26, 2026Last filing: 10-Q on Jul 21, 2026Score 12/3025% above fair value
$232.23−4.75 (-2.00%)

Close on Oct 30, 2026Market cap $163.25BP/E 41.2Yield –

Danaher Devicor Medical / Mammotome by Year

Devicor Medical / Mammotome (Breast Biopsy & Cancer Diagnostics) — FDA 510(k) Clearances

Danaher Devicor Medical / Mammotome: 0 in FY2025, down 100.0% from a year earlier. That is the lowest of the 10 years on record here.

Latest, FY2025
0
Period ended Dec 31, 2025
Change on a year earlier
-100.0%
3 in FY2024
History
10 years
Since FY2016
Sources
1
U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE)

Where the FY2025 figure comes from

Source: U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗

Reported in U.S. FDA openFDA Device 510(k) Clearances API.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Cite this data

StockData. (2026). Danaher Devicor Medical / Mammotome, annual FY2016–FY2025 [Data set]. Compiled from Danaher SEC filings and investor materials. https://stockdatahq.com/stocks/dhr/kpis/ext-fda-510k-mammotome-devicor

See every metric in the Danaher KPI table. Data updated Nov 2, 2026.